Record 30% growth, but PAT lags capex drag; margins solid underlying
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Beat prior guidance: 30% revenue > 'high teens' (13–19%); 20.4% underlying EBITDA > 20% target. 16-quarter track record of double-digit EBITDA growth intact.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue momentum (30% YoY, underlying 20.3%) and beat on underlying EBITDA margins (20.4% vs 20% target) validate core business resilience and pricing power. However, PAT growth lags sharply (4.5% vs 30% revenue) due to capex-driven depreciation and ETR headwinds. Merger closure by Q4 FY27 adds structural upside (US$35–50M synergies), but execution risk and Europe operational instability (2–3 quarters to stabilize) present near-term headwinds.
₹1567.4 Cr
Revenue · +30% YoY₹110.9 Cr
Reported PAT · +4.5% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Record 30% YoY revenue growth, highest ever
MET₹1567.4 Cr, 30% YoY confirmed; Q1 FY27 was 25%
Underlying EBITDA margin 20.4% on ex-raw-material basis
METReported EBITDA margin 18.9% (lower due to 'mathematics of higher cost, higher price'); underlying basis consistent with prior guidance
B&C growth 42.9%, now largest category (exceeded Oral Care in Sept)
METOral Care 19.2%; B&C exceptional, strategic shift validated by results
16 consecutive quarters of double-digit EBITDA growth
METQ2 EBITDA growth 17.6% YoY; consistent with multi-quarter track record
PAT grew 5.6% in quarter due to depreciation, ETR, forex
METDelivered PAT +4.5% YoY; cited headwinds (higher depreciation from INR3.15B H1 capex, ETR rise, adverse forex) suppress profit leverage despite 30% revenue
Earnings quality
What changed since the last call
Revenue guidance reiterated at high teens
NeutralPrior call: 'high teens for next few quarters.' This call: ~20% for next 2 quarters. Consistent reaffirmation; no raise despite 30% beat this quarter. Management signals 'prudence.'
EBITDA margin target maintained at 20%+
NeutralPrior: 20% underlying. This quarter: 20.4% delivered. On track; no upward revision despite strong Q.
B&C market share gain accelerating
Upgrade42.9% growth, 130 bps global market share gain, now largest segment (exceeded Oral Care in Sept). Strategic pivot validated faster than expected.
Europe margin pressure acknowledged as temporary
DowngradePoland centralization took 6–9 months vs expected timeline; outsourcing costs elevated; stabilization 2–3 quarters away. Quality/timeline miss on execution.
The Q&A
Analysts pressed on capex justification, Europe margin dip, synergy size, and revenue guidance credibility. Management held firm on capex ROI thesis (growth-oriented), provided detailed Poland timeline rationale, quantified synergy range (US$35–50M over 3 years), and emphasized 'prudence' in 20% growth forecast. No major concessions; tone remained confident but transparent.
Capex intensity and support — Sanjesh Jain, ICICI Securities
AnsweredCapex INR3.15B in H1, will remain at this level in H2. Full year ~INR625–700 Cr. Driven by B&C momentum and need to build capacity ahead of curve. Growth-oriented strategy; will moderate over time as capacity utilizes.
Europe performance decline — Sanjesh Jain, ICICI Securities
AnsweredPoland centralization project caused regulatory delays (6–9 months longer than expected). Now fully approved; transitioning operations. Will take another 2–3 quarters to fully stabilize and get margins back to desired levels. Operational challenges deeper than originally anticipated.
Margin recovery path — Raman KV, Sequent Investments
PartialFully recovered raw material cost inflation through pricing this quarter (and prior). Underlying EBITDA margin 20.4%, on track at 20% target. On Indovida synergies: US$35–50M over 3 years; most are growth-related. Larger proportion will be top-line, some cost savings but bulk on growth.
Revenue guidance credibility — Sameer Gupta, India Infoline
AnsweredWe believe we will be on high end of guidance (closer to 20%). Yes, we might say we are being prudent. Prices will moderate a bit; there is no real change [to guidance]. We should see good top line in H2 as well.
Merger timing and combined entity outlook — Ashish Upganlawar, InvestQ PMS
PartialExpecting merger closure by Q4 FY27. Q4 results hopefully consolidated, but dependent on NCLT approvals pending. Post-merger, we will provide combined guidance. Both businesses grown well; synergies US$35–50M over 3 years in business; debt-to-EBITDA will be ~0.2–0.25, enabling growth investments.
B&C expansion capex and ramp — Bharat Sheth, Quest Investment Managers
AnsweredLarge part is growth capex, mostly brownfield. Last greenfield was Thailand. Most are in existing capex locations with regulatory/customer approvals already in place. Ramp already visible: within 30% growth, B&C grew 40%. Capacity utilization 60–65% on rated capacity (normal operating range).
Geographic expansion opportunity — Pragyam Laddha, Omni Management
AnsweredYes. Indovida strong in Vietnam, Nigeria, Ghana, Tanzania, Morocco. After merger closure, we will evaluate country-by-country for capacity and synergies. Indovida is cash-rich, no debt; post-merger balance sheet very strong (0.2–0.25 debt-to-EBITDA), enabling inorganic opportunities.
B&C market share and growth drivers — Shivakshi Bhardwaj, Retail Investor
AnsweredBoth happening. In high-share markets like India, growth is existing customer wallet + market growth + share gains. In lower-share markets (Africa, China), growth is new customer entry + white-space capture. Margin profile similar across (Oral and B&C both ~44% each by size). Geographies vary by mix/customer profile.
Gross margin sustainability — Bharat Sheth, Quest Investment Managers
Answered56.7% is optical; mix of higher costs and higher prices both in numerator/denominator. Underlying gross contribution is 60.5% (ex inflationary cost). Margins look good. Leverage question is separate: we invested in capex/opex for growth; not taking additional leverage despite strong growth.
Price sustainability and volume growth mix — Mihir Shah, Nomura
Answered30% is revenue growth, not volume growth. Corrected for cost inflation, underlying is 20.3% volume growth. Both categories performing well; growth will be in range of ~20% next 2 quarters; prices will moderate at this point in time. We're being prudent in suggesting these growth numbers.
Guidance
High-teens revenue growth for next 2 quarters (~20% expected)
HighManagement 'being prudent'; prices will moderate; volume momentum strong (20.3% underlying after inflation adjustment). FY27 full-year ~₹5,900 Cr implied (~18–20% for H2 after 30% H1).
FY27 full-year revenue ~₹5,900 Cr
HighAnalyst calculation: if H1 ~₹1500 Cr (blended from context), H2 ~₹4,400 Cr implies ~20% H2 growth. Consistent with 'high teens' for next quarters.
Underlying EBITDA margin 20%+ maintained for FY27
HighQ2 delivered 20.4%, beating target. Management 'on track' despite cost pressures and capex depreciation. Reported margin 18.9% lower due to mix accounting (higher cost + higher price both in numerator/denominator).
FY27 capex INR625–700 Cr (elevated, ~90% increase YoY)
HighH1 capex INR3.15B; H2 similar level. Driven by B&C capacity, U.S. printing/decoration investments, Thailand greenfield (completed). Growth-oriented; will moderate once capacity utilizes.
Risks the call surfaced
Operational—Europe
MediumPoland printing facility regulatory approvals took 6–9 months longer than planned. Outsourcing costs elevated. Stabilization 2–3 quarters out. If timeline slips further, H2 margins at risk.
Financial—PAT leverage
High30% revenue growth delivered only 4.5% PAT growth. Drivers: INR3.15B H1 capex → higher D&A; ETR rise to ~23%; forex headwinds. Limited profit expansion visible despite topline strength. Near-term ROI on growth investments will be diluted.
Strategic—Merger integration
MediumIndovida merger closure expected Q4 FY27. NCLT approval still pending (no timeline given). Synergy realization (US$35–50M over 3 years) contingent on smooth integration. Execution risk on post-merger reorganization.
Market—Price sustainability
MediumManagement reiterated 'prices will moderate at this point in time.' Current 30% growth mix is pricing (raw material inflation recovery) + volume (20.3% underlying). As inflation cools, pricing support fades. Revenue growth guidance capped at 'high teens' (~20%) for next quarters.
Financial—Capex ROI uncertainty
MediumCapex is ~90% increase YoY, driven by B&C expansion (greenfield in U.S., brownfield globally, Thailand entry). Large-scale investments carry execution risk. If capacity utilization stays below 70–75% or market conditions soften, ROI may disappoint.
Management
Score 8/10. Clear, direct, data-backed. Hemant fielded detailed questions on capex, Europe, margins without deflection. Acknowledged challenges (Poland delay, ETR impact). Some hedging on price visibility and merger synergy specifics (ranges given vs point estimates). Strong: 16 quarters consecutive double-digit EBITDA growth. Hit/beat prior guidance (30% revenue > 'high teens'; 20.4% EBITDA > 20% target). Europe delay a miss on timeline (6–9 months), but being addressed actively. B&C growth (42.9%) ahead of expectations, validating strategy.
1 · Q3–Q4 FY27
Europe Poland operations stabilize; margin recovery visible. Currently 2–3 quarters out.
2 · Q4 FY27
Indovida merger closure; post-merger integration begins; synergy realization path visible.
3 · Q4 FY27
Indovida results become public; growth/margin profile of combined entity becomes clear.
Merger closure by Q4 FY27 adds structural upside (US$35–50M synergies), but execution risk and Europe operational instability (2–3 quarters to stabilize) present near-term headwinds.
Informational and educational content only. Not investment advice.